DORZASOPT

Dorzasopt (Eye Drops)
(Dorzolamide / Timolol)

 

COMPOSITION
Each ml contains dorzolamide 20 mg, timolol 54 mg.

THERAPEUTIC INDICATIONS

- Increased intraocular pressure;
- Open-angled glaucoma (including pseudoexfoliative glaucoma and other types of secondary open-angled glaucoma).

CONTRAINDICATIONS
Hypersensibility to preparation components;
- Severe renal failure (CC less than 30 ml/mins);
- Hyperhloremic acidosis;
- Sinus bradycardia;
- AV-blockade of I and II degrees;
- Expressed heart failure;
- Cardiogenic shock;
- Dystrophic processes in cornea;
- Bronchial asthma (including the history);
- Severe obstructive lung disease;
- Severe allergic inflammation of nasal mucosa;
- Children and teenagers;
- Pregnancy.

ADVERSE EFFECTS
Generally the preparation is well tolerated. Inflammation of eyelid, irritation, dryness, visual disturbances, allergic reactions are possible. Systemic adverse effects are generally less expressed and do not lead to the preparation withdrawal.

DOSAGE AND ADMINISTRATION
1 drop of the preparation is instilled into conjunctival sac of an affected eye 2 times/day. While co-administrated with other ophthalmologic products interval between instillation should be not less than 15 minutes.

PREGNANCY AND LACTATION
Administration in pregnancy is contraindicated. Breast-feeding should be stopped during the treatment with the drug.

PRECAUTIONS
Eye drops contain preserving agent benzalkonium chloride therefore individuals wearing hard contact lenses should remove them before instillation of a product and wear again not less than in 15 minutes after instillation. One should not wear soft contact lenses during treatment with the drug as preserving agent can affect the eye.

MANUFACTURED FORM
5 ml in plastic vial with dropping stopper and screw cap, supplied with guard ring. Vial in carton box with packaging leaflet